Neoadjuvant chemotherapy for patients with liver metastases from colorectal cancer

References

• Jemal A, Ward E, Hao Y et al. Trends in the leading causes of death in the United States, 1970–2002. JAMA294, 1255–1259 (2005).
   PubMed Web of Science ®Google Scholar
• Welch JP, Donaldson GA. The clinical correlation of an autopsy study of recurrent colorectal cancer. Ann. Surg.189, 496–502 (1979).
   PubMed Web of Science ®Google Scholar
• Weiss L, Grundmann E, Torhorst J, Scheele J. Factors influencing the natural history of colorectal liver metastses. Lancet342, 1405–1410 (1994).
   Google Scholar
• Bengtsson G, Carlsson G, Hafstrom L et al. Natural history of patients with untreated liver metastases from colorectal cancer. Am. J. Surg.141, 586–589 (1981).
   PubMed Web of Science ®Google Scholar
• Rougier P, Milan C, Lazorthes F et al. Prospective study of prognostic factors in patients with unresected hepatic metastases from colorectal cancer. Br. J. Surg.82, 1397–1400 (1995).
   PubMedGoogle Scholar
• Fong Y, Cohen AM, Fortner JG et al: Liver resection for colorectal metastases. J. Clin. Oncol.15, 938–946 (1997).
   PubMed Web of Science ®Google Scholar
• Yamamoto J, Shimada K, Kosuge T et al. Factors influencing survival of patients undergoing hepatectomy for colorectal metastases. Br. J. Surg.83, 332–337 (1999).
   Google Scholar
• Fusai G, Davidson BR. Management of colorectal liver metastses. Colorectal Dis.5, 2–23 (2003).
   Google Scholar
• Tourningand C, Andre T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomised GERCOR Study. J. Clin. Oncol.22, 229–237 (2004).
   Google Scholar
• Wagner JS, Adson MA, Van Heerden JA et al. The natural history of hepatic metastases from colorectal cancer. A comparison with resective treatment. Ann. Surg.199, 502–508 (1984).
   PubMed Web of Science ®Google Scholar
• Scheele J, Stangl R, Altendorf-Hofmann A. Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br. J. Surg.77, 1241–1246 (1990).
   PubMed Web of Science ®Google Scholar
• Doci R, Gennari L, Bignami P et al. One hundred patients with hepatic metastases from colorectal cancer treated with resection: analysis of prognostic determinants. Br. J. Surg.78, 797–801 (1991).
   PubMed Web of Science ®Google Scholar
• Fong Y, Fortner J, Sun RL et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann. Surg.230–309–321 (1999).
   Google Scholar
• Minagawa M, Makuuchi M, Torzilli G et al. Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer: long term results. Ann. Surg.231, 487–499 (2000).
   PubMed Web of Science ®Google Scholar
• Ercolani G, Grazi GL, Ravaioli M et al. Liver resection for multiple colorectal metastases: influence of parenchymal involvement and total tumour volume vs. number or location, on long term survival. Arch. Surg.137, 1187–1192 (2002).
   PubMedGoogle Scholar
• Adam R, Pascal G, Azoulay D et al. Liver resection for colorectal metastases . The third hepatectomy. Ann. Surg.6, 871–884 (2003).
   Google Scholar
• Hughes KS, Simon R, Songhorabodi S et al. Resection of the liver colorectal carcinoma metastases: a multi-institutional study patterns of recurrence. Surgery100, 278–284 (1986).
   PubMed Web of Science ®Google Scholar
• Gayowski TJ, Iwatsuki S, Madariaga JR et al. Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathological risk factors. Surgery116, 703–711 (1994).
   PubMed Web of Science ®Google Scholar
• Scheele J, Stang R, Altendorf-Hoffmann A et al. Resection of colorectal liver metastases. World J. Surg.19, 59–71 (1995).
   PubMed Web of Science ®Google Scholar
• Fong Y, Blumgart LH, Fortner JG et al. Pancreatic or liver resection for malignancy is safe and effective for the elderly. Ann. Surg.222, 426–437 (1995).
   PubMed Web of Science ®Google Scholar
• Nordlinger B, Guiguet M, Vaillant JC et al. Surgical resection of colorectal carcinoma metastases to the liver: a prognostic scoring system to improve case selection, based on 1568 patients: Association Française de Chirurgie. Cancer77, 1254–1262 (1996).
   PubMed Web of Science ®Google Scholar
• Jamison RL, Donohue JH, Nagorney DM et al. Hepatic resection for metastatic colorectal cancer results in cure for some patients. Arch. Surg.132, 505–511 (1997).
   PubMed Web of Science ®Google Scholar
• Poston GJ, Adam R, Alberts S et al. OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer. J. Clin. Oncol.23, 7125–7134 (2006).
   Google Scholar
• Headrick JR, Miller DL, Nagorney DM et al. Surgical treatment of hepatic and pulmonary metastases from colon cancer. Ann. Thorac. Surg.71, 975–979 (2001).
   PubMedGoogle Scholar
• Regnard JF, Grunenwald D, Spaggiari L et al. Surgical treatment of hepatic and pulmonary metastases from colorectal cancers. Ann. Thorac. Surg.66, 214–218 (1998).
   PubMed Web of Science ®Google Scholar
• Elias D, Sideris L, Pocard M et al. Results of R0 resection for colorectal liver metastases associated with extrahepatic disease. Ann. Surg. Oncol.11, 274–280 (2004).
   PubMed Web of Science ®Google Scholar
• Alberts SR, Horvath WL, Sternfeld WC et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group Phase II study. J. Clin. Oncol.23, 9243–9249 (2005).
   PubMed Web of Science ®Google Scholar
• Finan PJ, Marshall RJ, Cooper EH et al. Factors affecting survival in patients presenting with synchronous hepatic metastases from colorectal cancer: a clinical and computer analysis. Br. J. Surg.72, 373–377 (1985).
   Google Scholar
• Goslin R, Steele G Jr, Zamcheck N et al: Factors influencing survival in patients with hepatic metastases from adenocarcinoma of the colon or rectum. Dis. Colon Rectum25, 749–754 (1982).
   Google Scholar
• Bismuth H, Adam R, Levi F et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann. Surg.224, 509–520 (1996).
   PubMed Web of Science ®Google Scholar
• Giacchetti S, Itzhaki M, Gruia G et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann. Oncol.10, 663–669 (1999).
   PubMed Web of Science ®Google Scholar
• Adam R, Avisar E, Ariche A et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann. Surg. Oncol.8, 347–353 (2001).
   PubMed Web of Science ®Google Scholar
• Nordlinger B. Surgery and chemotherapy combined for colorectal liver metastases. Adv. Exp. Med. Biol.574, 29–30 (2006).
   Google Scholar
• Delaunoit T, Alberts SR, Sargent DJ et al. Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741. Ann. Oncol.16, 425–429 (2005).
   PubMed Web of Science ®Google Scholar
• Souglakos J, Androulakis N, Syrigos K et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised Phase III trial from the Hellenic Oncology Research Group (HORG). Br. J. Cancer94, 798–805 (2006).
   PubMed Web of Science ®Google Scholar
• Masi G, Cupini S, Marcucci L et al. Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer. Ann. Surg. Oncol.13, 58–65 (2006).
   PubMed Web of Science ®Google Scholar
• Falcone A, Masi G, Murr R et al. Biweekly irinotecan, oxaliplatin, and infusional 5FU/LV (FOLFOXIRI) versus FOLFIRI as first-line treatment of metastatic colorectal cancer (MCRC): results of a randomized, Phase III trial by the Gruppo Oncologico Nord Ovest (GONO). Presented at: ASCO 2006 Gastrointestinal Cancers Symposium. San Francisco, CA, USA, 26–28 January 2006 (Abstract 227).
   Google Scholar
• Wein A, Riedel C, Kockerling F et al. Impact of surgery on survival in palliative patients with metastatic colorectal cancer after first line treatment with weekly 24-hour infusion of high-dose 5-fluorouracil and folinic acid. Ann. Oncol.12, 1721–1727 (2001).
   Google Scholar
• Pozzo C, Basso M, Cassano A et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann. Oncol.15, 933–939 (2004).
   PubMed Web of Science ®Google Scholar
• Abad A, Anton A, Massutti B et al. Resectability of liver metastases in patients with advanced colorectal cancer after treatment with the combination of oxalipaltin, irinotecan, and 5FU. Final results of a Phase II study. Proc. Am. Soc. Clin. Oncol.23, 275 (2005) (Abstract 3618).
   Google Scholar
• Muratore A, Zorzi D, Bouzari H et al. Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy? Ann. Surg. Oncol.14, 766–770 (2007).
   PubMed Web of Science ®Google Scholar
• Scoggins CR, Meszoely IM, Blanke CD et al. Nonoperative management of primary colorectal cancer in patients with stage IV disease. Ann. Surg. Oncol.6, 651–657 (1999).
   PubMed Web of Science ®Google Scholar
• Muratore A, Polastri R, Bouzari H, Vergara V, Ferrero A, Capussotti L. Repeat hepatectomy for colorectal liver metastases: a worthwhile operation? J. Surg. Oncol.76, 127–132 (2001).
   PubMed Web of Science ®Google Scholar
• Petrowsky H, Gonen M, Jarnagin W et al. Second liver resections are safe and effective treatment for recurrent hepatic metastases from colorectal cancer: a bi-institutional analysis. Ann. Surg.235, 863–871 (2002).
   PubMedGoogle Scholar
• Capussotti L, Muratore A, Mulas MM, Massucco P, Aglietta M. Neoadjuvant chemotherapy and resection for initially irresectable colorectal liver metastases. Br. J. Surg.93(8), 1001–1006 (2006).
   Google Scholar
• No authors listed. Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. Meta-Analysis Group in Cancer. J. Natl Cancer Inst.88, 252–258 (1996).
   PubMed Web of Science ®Google Scholar
• Kemeny N, Jarnagin J, Paty P et al. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J. Clin. Oncol.23, 4888–4896 (2005).
   PubMed Web of Science ®Google Scholar
• Kemeny N, Gonen M, Sullivan D et al. Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer. J. Clin. Oncol.19, 2687–2695 (2001).
   PubMed Web of Science ®Google Scholar
• Domont J, Pawlik TM, Boige V et al. Catalytic subunit of human telomerase reverse transcriptase is an independent predictor of survival in patients undergoing curative resection of hepatic colorectal metastases: a multicenter analysis. J. Clin. Oncol.23, 3086–3093 (2005).
   PubMedGoogle Scholar
• Smith DL, Soria JC, Morat L et al. Human telomerase reverse transcriptase (hTERT) and Ki-67 are better predictors of survival than established clinical indicators in patients undergoing curative hepatic resection for colorectal metastases. Ann. Surg. Oncol.11, 45–51 (2004).
   PubMed Web of Science ®Google Scholar
• Mehta KR, Nakao K, Zuraek MB et al. Fractional genomic alteration detected by array-based comparative genomic hybridization independently predicts survival after hepatic resection for metastatic colorectal cancer. Clin. Cancer Res.11, 1791–1797 (2005).
   Google Scholar
• Takahashi Y, Nagata T, Ishii Y et al. Up-regulation of vitamin D3 up-regulated protein 1 gene in response to 5-fluorouracil in colon carcinoma SW620. Oncol. Rep.9, 75–79 (2002).
   PubMedGoogle Scholar
• Clarke PA, George ML, Easdale S et al. Molecular pharmacology of cancer therapy in human colorectal cancer by gene expression profiling. Cancer Res.63, 6855–6863 (2003).
   PubMed Web of Science ®Google Scholar
• Park JS, Young Yoon S, Kim JM et al. Identification of novel genes associated with the response to 5-FU treatment in gastric cancer cell lines using a cDNA microarray. Cancer Lett.214, 19–33 (2004).
   PubMed Web of Science ®Google Scholar
• Peters GJ, van der Wilt CL, van Groeningen CJ et al. Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: implications for treatment with fluorouracil. J. Clin. Oncol.12, 2035–2042 (1994).
   PubMed Web of Science ®Google Scholar
• Noordhuis P, Holwerda U, van der Wilt CL et al. 5-Fluorouracil incorporation into RNA and DNA in relation to thymidylate synthase inhibition of human colorectal cancers. Ann. Oncol.15, 1025–1032 (2004).
   PubMed Web of Science ®Google Scholar
• Aschele C, Debernardis D, Casazza S et al. Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. J. Clin. Oncol.17, 1760–1770 (1999).
   PubMed Web of Science ®Google Scholar
• Aschele C, Debernardis D, Tunesi G et al. Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil. Clin. Cancer Res.6, 4797–4802 (2000).
   PubMed Web of Science ®Google Scholar
• Smoremburg CH, Peters GJ, van Groeningen CJ et al. Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase. Ann. Oncol.17, 35–42 (2006).
   Google Scholar
• Boyer J, Allen WL, McLean EG. Pharmacogenomic identification of novel determinants of response to chemotherapy in colon cancer. Cancer Res.66, 2765–2777 (2006).
   PubMed Web of Science ®Google Scholar
• Gonen M, Hummer A, Zervoudakis A et al. Thymidylate synthase expression in hepatic tumors is a predictor of survival and progression in patients with resectable metastatic colorectal cancer. J. Clin. Oncol.21, 406–412 (2003).
   PubMed Web of Science ®Google Scholar
• Weber JC, Nakano H, Bachellier P et al. Is a proliferation index of cancer cells a reliable prognostic factor after hepatectomy in patients with colorectal liver metastases? Am. J. Surg.182, 81–88 (2001).
   Google Scholar
• Onodera H, Mori A, Nagayama S et al. Fas/CD95 signaling rather than angiogenesis or proliferative activity is a useful prognostic factor in patients with resected liver metastases from colorectal cancer. Int. J. Colorectal Dis.20, 477–484 (2005).
   Google Scholar
• Costa A, Doci R, Mochen C, Bignami P et al. Cell proliferation-related markers in colorectal liver metastases: correlation with patient prognosis. J. Clin. Oncol.15, 2008–2014 (1997).
   PubMed Web of Science ®Google Scholar
• Haddad R, Ogilvie RT, Croitoru M et al. Microsatellite instability as a prognostic factor in resected colorectal cancer liver metastases. Ann. Surg. Oncol.11, 977–982 (2004).
   PubMed Web of Science ®Google Scholar
• Rubbia-Brandt L, Audard V, Sartoretti P et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann. Oncol.15, 460–466 (2004).
   PubMed Web of Science ®Google Scholar
• Karoui M, Penna C, Amin-Hashem M et al. Influence of preoperative chemotherapy on the risk of major hepatectomia for colorectal liver metastases. Ann. Surg.243, 1–7 (2006).
   PubMed Web of Science ®Google Scholar
• Vauthey JN, Pawlik TM, Ribero D et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J. Clin. Oncol.24(13), 2065–2072 (2006).
   PubMed Web of Science ®Google Scholar
• Aloia T, Sebagh M, Plasse M et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J. Clin. Oncol.24(31), 4983–4990 (2006).
   PubMed Web of Science ®Google Scholar
• Fernandez FG, Ritter J, Goodwin JW et al. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resecability of hepatic colorectal metastases. J. Am. Coll. Surg.200(6), 845–853 (2005).
   PubMed Web of Science ®Google Scholar
• Nordlinger B, Benoist S. Benefits and risks of neoadjuvant therapy for liver metastases. J. Clin. Oncol.24(31), 4954–4955 (2006).
   Google Scholar
• Scappaticci FA, Fehrenbacher L, Cartwright T et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J. Surg. Oncol.91, 173–180 (2005).
   PubMed Web of Science ®Google Scholar
• Ellis LM, Curley SA, Grothey A. Surgical resection after downsizing of colorectal metastases in the era of bevacizumab. J. Clin. Oncol.23, 4853–4855 (2005).
   PubMed Web of Science ®Google Scholar
• Pawlik TM, Scoggins CR, Zorzi D et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann. Surg.241, 715–724 (2005).
   PubMed Web of Science ®Google Scholar
• Capussotti L, Vigano’ L, Ferrero A et al. Timing of resection of liver metastases synchronous to colorectal tumor: proposal of prognosis-based decisional model. Ann. Surg. Oncol.14, 1143–1150 (2007).
   PubMed Web of Science ®Google Scholar
• Benoist S, Brouquet A, Penna C et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J. Clin. Oncol.24, 3939–3945 (2006).
   PubMed Web of Science ®Google Scholar
• Portier G, Elias D, Bouche O et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J. Clin. Oncol.24(31), 4976–4982 (2006).
   PubMed Web of Science ®Google Scholar